A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-05-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lymphomasubjectpriorcelltumor
  Phrases that lowered it: doseaccordingmonths beforehepaticmoderate
• Sponsor's past termination rate: 38.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 33 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 24.3% (raises risk) · Drug's FDA history
• Minimum age: 16 (raises risk) · Who can join
• Drug's FAERS reports before start: 4002 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma NCT03939182 · started 2019 · scored riskier than 43% of active trials completed
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma NCT02956382 · started 2017 · scored riskier than 89% of active trials completed
• Phase II Trial GA101 Inbrutinib B CLL NCT02666898 · started 2015 · scored riskier than 88% of active trials completed
• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma NCT02736617 · started 2016 · scored riskier than 98% of active trials completed
• A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma NCT03136497 · started 2017 · scored riskier than 80% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.